ACRS Fundamental Analysis - ACLARIS THERAPEUTICS INC

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ACRS. ACRS was compared to 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ACRS as it has an excellent financial health rating, but there are worries on the profitability. ACRS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ACRS had negative earnings in the past year.

ACRS had a negative operating cash flow in the past year.

In the past 5 years ACRS always reported negative net income.

ACRS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -71.19%, ACRS is doing worse than 68.02% of the companies in the same industry.

ACRS's Return On Equity of -102.21% is in line compared to the rest of the industry. ACRS outperforms 41.12% of its industry peers.

		Industry Rank	Sector Rank
ROA	-71.19%
ROE	-102.21%
ROIC	N/A

ROA(3y)-46.3%

ROA(5y)-49.43%

ROE(3y)-61.73%

ROE(5y)-73.31%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 10.21%, ACRS perfoms like the industry average, outperforming 49.75% of the companies in the same industry.

In the last couple of years the Gross Margin of ACRS has grown nicely.

The Profit Margin and Operating Margin are not available for ACRS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	10.21%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-15.2%

GM growth 5Y35.7%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ACRS has more shares outstanding

The number of shares outstanding for ACRS has been increased compared to 5 years ago.

ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -5.21, we must say that ACRS is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -5.21, ACRS is in line with its industry, outperforming 40.61% of the companies in the same industry.

ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.21

ROIC/WACCN/A

WACC9.8%

2.3 Liquidity

A Current Ratio of 3.88 indicates that ACRS has no problem at all paying its short term obligations.

The Current ratio of ACRS (3.88) is better than 64.47% of its industry peers.

ACRS has a Quick Ratio of 3.88. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 3.88, ACRS is doing good in the industry, outperforming 65.48% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.88
Quick Ratio	3.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ACRS have decreased strongly by -67.07% in the last year.

The Revenue for ACRS has decreased by -47.56% in the past year. This is quite bad

ACRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.65% yearly.

EPS 1Y (TTM)-67.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%13.33%

Revenue 1Y (TTM)-47.56%

Revenue growth 3Y40.43%

Revenue growth 5Y34.65%

Sales Q2Q%-35.76%

3.2 Future

ACRS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.69% yearly.

The Revenue is expected to grow by 25.48% on average over the next years. This is a very strong growth

EPS Next Y65.21%

EPS Next 2Y28.05%

EPS Next 3Y16.18%

EPS Next 5Y8.69%

Revenue Next Year-49.69%

Revenue Next 2Y-26.62%

Revenue Next 3Y-18.64%

Revenue Next 5Y25.48%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ACRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ACRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ACRS's earnings are expected to grow with 16.18% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y28.05%

EPS Next 3Y16.18%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ACRS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ACLARIS THERAPEUTICS INC

NASDAQ:ACRS (9/19/2025, 8:00:00 PM)

After market: 1.87 -0.04 (-2.09%)

1.91

-0.04 (-2.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-07 2025-08-07/bmo

Earnings (Next)11-04 2025-11-04/bmo

Inst Owners87.74%

Inst Owner Change-0.94%

Ins Owners2.58%

Ins Owner Change0.66%

Market Cap206.91M

Analysts84.29

Price Target8.01 (319.37%)

Short Float %5.61%

Short Ratio5.53

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)1.97%

Min EPS beat(2)-0.13%

Max EPS beat(2)4.07%

EPS beat(4)1

Avg EPS beat(4)-534.44%

Min EPS beat(4)-1788.67%

Max EPS beat(4)4.07%

EPS beat(8)5

Avg EPS beat(8)-247.68%

EPS beat(12)9

Avg EPS beat(12)-160.59%

EPS beat(16)12

Avg EPS beat(16)-119.32%

Revenue beat(2)2

Avg Revenue beat(2)19.17%

Min Revenue beat(2)11.41%

Max Revenue beat(2)26.93%

Revenue beat(4)3

Avg Revenue beat(4)81.65%

Min Revenue beat(4)-40.15%

Max Revenue beat(4)328.42%

Revenue beat(8)7

Avg Revenue beat(8)167.28%

Revenue beat(12)10

Avg Revenue beat(12)226.62%

Revenue beat(16)10

Avg Revenue beat(16)166.99%

PT rev (1m)0%

PT rev (3m)-3.79%

EPS NQ rev (1m)1.1%

EPS NQ rev (3m)9.25%

EPS NY rev (1m)0%

EPS NY rev (3m)8.44%

Revenue NQ rev (1m)3.51%

Revenue NQ rev (3m)4.51%

Revenue NY rev (1m)4.36%

Revenue NY rev (3m)-2.42%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	12.32
P/FCF	N/A
P/OCF	N/A
P/B	1.57
P/tB	1.57
EV/EBITDA	N/A

EPS(TTM)-1.37

EYN/A

EPS(NY)-0.54

Fwd EYN/A

FCF(TTM)-0.43

FCFYN/A

OCF(TTM)-0.09

OCFYN/A

SpS0.15

BVpS1.22

TBVpS1.22

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-71.19%
ROE	-102.21%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	10.21%
FCFM	N/A

ROA(3y)-46.3%

ROA(5y)-49.43%

ROE(3y)-61.73%

ROE(5y)-73.31%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-15.2%

GM growth 5Y35.7%

F-Score2

Asset Turnover0.09

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	6508.33%
Cap/Sales	218.64%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.88
Quick Ratio	3.88
Altman-Z	-5.21

F-Score2

WACC9.8%

ROIC/WACCN/A

Cap/Depr(3y)1560.12%

Cap/Depr(5y)949.63%

Cap/Sales(3y)66.06%

Cap/Sales(5y)41.94%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-67.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%13.33%

EPS Next Y65.21%

EPS Next 2Y28.05%

EPS Next 3Y16.18%

EPS Next 5Y8.69%

Revenue 1Y (TTM)-47.56%

Revenue growth 3Y40.43%

Revenue growth 5Y34.65%

Sales Q2Q%-35.76%

Revenue Next Year-49.69%

Revenue Next 2Y-26.62%

Revenue Next 3Y-18.64%

Revenue Next 5Y25.48%

EBIT growth 1Y-1.1%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-17.73%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y37.72%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y86.49%

OCF growth 3YN/A

OCF growth 5YN/A

ACLARIS THERAPEUTICS INC (ACRS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens